CS
CLVS

Candriam SCA’s Clovis Oncology, Inc. CLVS Stock Holding History

Candriam SCA’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-533,832
Closed -$2.46M – 946
2021
Q1 		$2.46M Hold
533,832
– – 0.02% 489
2020
Q4 		$2.56M Sell
533,832
-851,803
-61% -$4.31M 0.02% 501
2020
Q3 		$8.08M Buy
1,385,635
+87,185
+7% +$522K 0.08% 268
2020
Q2 		$8.77M Buy
1,298,450
+298,535
+30% +$2.26M 0.09% 236
2020
Q1 		$10.2M Buy
999,915
+62
+0% +$497 0.11% 209
2019
Q4 		$10.4M Sell
999,853
-131,270
-12% -$955K 0.11% 211
2019
Q3 		$4.45M Buy
1,131,123
+23,000
+2% +$186K 0.06% 342
2019
Q2 		$16.4M Buy
1,108,123
+326,500
+42% +$5.9M 0.2% 112
2019
Q1 		$19.4M Buy
781,623
+488,523
+167% +$12.2M 0.25% 90
2018
Q4 		$5.26M Buy
293,100
+76,000
+35% +$1.55M 0.08% 272
2018
Q3 		$6.38M Buy
217,100
+21,100
+11% +$817K 0.08% 273
2018
Q2 		$8.91M Buy
196,000
+21,500
+12% +$1.05M 0.14% 188
2018
Q1 		$9.21M Hold
174,500
– – 0.16% 172
2017
Q4 		$11.9M Sell
174,500
-43,000
-20% -$3.01M 0.21% 134
2017
Q3 		$17.9M Buy
217,500
+48,500
+29% +$3.84M 0.31% 81
2017
Q2 		$15.8M Buy
169,000
+49,000
+41% +$3M 0.3% 85
2017
Q1 		$7.64M Sell
120,000
-11,000
-8% -$669K 0.15% 175
2016
Q4 		$5.82M Sell
131,000
-18,000
-12% -$634K 0.13% 188
2016
Q3 		$5.37M Buy
149,000
+102,000
+217% +$2.19M 0.13% 182
2016
Q2 		$645K Buy
47,000
+15,000
+47% +$219K 0.02% 520
2016
Q1 		$611K Sell
32,000
-4,300
-12% -$91K 0.02% 517
2015
Q4 		$1.27M Sell
36,300
-6,500
-15% -$419K 0.03% 358
2015
Q3 		$3.94M Sell
42,800
-17,200
-29% -$1.49M 0.1% 234
2015
Q2 		$5.27M Sell
60,000
-10,000
-14% -$856K 0.11% 232
2015
Q1 		$5.2M Sell
70,000
-39,000
-36% -$2.75M 0.1% 248
2014
Q4 		$6.1M Buy
+109,000
New +$5.73M 0.13% 201

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Candriam SCA's CLVS Position: Q2 2021 in Review

Candriam SCA sold out of Clovis Oncology, Inc. (CLVS) in Q2 2021, closing a stake of 533,832 shares — an estimated $2.46M sold.

Candriam SCA first reported a position in CLVS in Q4 2014 and held it in 26 quarters. The position peaked at $19.4M in Q1 2019. 160 funds tracked by Wall St. Rank hold CLVS as of Q2 2021.

  • Candriam SCA reported no remaining Clovis Oncology, Inc. position as of Q2 2021 after selling out during the quarter.
  • Candriam SCA sold 533,832 Clovis Oncology, Inc. shares in Q2 2021, an estimated $2.46M.
  • Candriam SCA first reported a position in Clovis Oncology, Inc. in Q4 2014 and held it in 26 quarters.
  • Candriam SCA's Clovis Oncology, Inc. position peaked at $19.4M in Q1 2019.
  • 160 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2021.

Based on Candriam SCA's 13F filing for Q2 2021, filed 20 Jul 2021.